KR20010033834A - 면역 특권 부위의 생성을 위한 착색된 망막 상피 세포의사용 - Google Patents

면역 특권 부위의 생성을 위한 착색된 망막 상피 세포의사용 Download PDF

Info

Publication number
KR20010033834A
KR20010033834A KR1020007007392A KR20007007392A KR20010033834A KR 20010033834 A KR20010033834 A KR 20010033834A KR 1020007007392 A KR1020007007392 A KR 1020007007392A KR 20007007392 A KR20007007392 A KR 20007007392A KR 20010033834 A KR20010033834 A KR 20010033834A
Authority
KR
South Korea
Prior art keywords
cells
rpe
site
biologically active
therapeutic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020007007392A
Other languages
English (en)
Korean (ko)
Inventor
앨런리차드씨.
콘펠트마이클엘.
키드웰윌리암알.
Original Assignee
타이탄 파마슈티칼스 인코퍼레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 타이탄 파마슈티칼스 인코퍼레이티드 filed Critical 타이탄 파마슈티칼스 인코퍼레이티드
Publication of KR20010033834A publication Critical patent/KR20010033834A/ko
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0618—Cells of the nervous system
    • C12N5/0621—Eye cells, e.g. cornea, iris pigmented cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/44—Vessels; Vascular smooth muscle cells; Endothelial cells; Endothelial progenitor cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/122—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells for inducing tolerance or supression of immune responses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/126—Immunoprotecting barriers, e.g. jackets, diffusion chambers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
    • C12N2506/08—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from cells of the nervous system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Vascular Medicine (AREA)
  • Diabetes (AREA)
  • Ophthalmology & Optometry (AREA)
  • Virology (AREA)
  • Developmental Biology & Embryology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pulmonology (AREA)
  • Cardiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Endocrinology (AREA)
KR1020007007392A 1998-01-02 1998-12-31 면역 특권 부위의 생성을 위한 착색된 망막 상피 세포의사용 Ceased KR20010033834A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US241398A 1998-01-02 1998-01-02
US09/002,413 1998-01-02
PCT/US1998/027730 WO1999034834A1 (en) 1998-01-02 1998-12-31 Use of pigmented retinal epithelial cells for creation of an immune privilege site

Publications (1)

Publication Number Publication Date
KR20010033834A true KR20010033834A (ko) 2001-04-25

Family

ID=21700636

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020007007392A Ceased KR20010033834A (ko) 1998-01-02 1998-12-31 면역 특권 부위의 생성을 위한 착색된 망막 상피 세포의사용

Country Status (8)

Country Link
US (1) US20060147437A1 (cg-RX-API-DMAC7.html)
EP (1) EP1044024A1 (cg-RX-API-DMAC7.html)
JP (1) JP2002500202A (cg-RX-API-DMAC7.html)
KR (1) KR20010033834A (cg-RX-API-DMAC7.html)
AU (1) AU759273B2 (cg-RX-API-DMAC7.html)
CA (1) CA2317115A1 (cg-RX-API-DMAC7.html)
NZ (1) NZ505459A (cg-RX-API-DMAC7.html)
WO (1) WO1999034834A1 (cg-RX-API-DMAC7.html)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7115256B1 (en) 1999-04-09 2006-10-03 Titan Pharmaceuticals, Inc. Methods of treating schizophrenia
JP2002281964A (ja) * 2000-12-26 2002-10-02 Sanyo Chem Ind Ltd 細胞生産方法
WO2002066620A2 (de) * 2001-02-21 2002-08-29 Stefan Kochanek Pigmentepithelzelle des auges, ihre herstellung und verwendung in der therapie einer augen- oder zns-erkrankung
DE10108412B4 (de) * 2001-02-21 2006-03-09 Cevec Pharmaceuticals Gmbh Pigmentepithelzelle des Auges, ihre Herstellung und Verwendung in der Therapie einer Augen- oder Nervenerkrankung
WO2003092723A1 (de) * 2002-05-03 2003-11-13 Nikolai Rainov Verwendung von fasl zur behandlung von neurodegenerativen erkrankungen
EP1551956A4 (en) 2002-07-12 2006-12-27 Univ Washington METHOD AND SYSTEMS FOR THE EXTENDED IN VITRO CULTURE OF NEURONAL CELLS
US20040156878A1 (en) * 2003-02-11 2004-08-12 Alireza Rezania Implantable medical device seeded with mammalian cells and methods of treatment
CA2937099A1 (en) * 2004-01-23 2005-08-04 Astellas Institute For Regenerative Medicine Improved modalities for the treatment of degenerative diseases of the retina
US7794704B2 (en) 2004-01-23 2010-09-14 Advanced Cell Technology, Inc. Methods for producing enriched populations of human retinal pigment epithelium cells for treatment of retinal degeneration
EP2209888B1 (en) 2007-10-12 2019-12-04 Astellas Institute for Regenerative Medicine Improved methods of producing rpe cells and compositions of rpe cells
IL281453B (en) 2009-11-17 2022-07-01 Astellas Inst For Regenerative Medicine Methods for preparing human rpe cells and pharmaceutical preparations of human rpe cells
IL287381B2 (en) * 2011-11-14 2024-04-01 Astellas Inst For Regenerative Medicine Pharmaceutical preparations of human rpe cells and uses thereof
CA3087238A1 (en) 2018-05-24 2019-11-28 Celanese EVA Performance Polymers Corporation Implantable device for sustained release of a macromolecular drug compound
CN111989068B (zh) 2018-05-24 2024-10-25 塞拉尼斯伊娃高性能聚合物公司 用于持续释放大分子药物化合物的可植入器件
EP3803866A4 (en) 2018-05-24 2022-03-16 Nureva Inc. METHOD, APPARATUS, AND COMPUTER READABLE MATERIALS FOR MANAGING SEMI-CONSTANT (PERSISTENT) SOUND SOURCES IN MICROPHONE CATCH/HOME AREAS
EP4329734A4 (en) 2021-04-26 2025-04-02 Celanese EVA Performance Polymers LLC Implantable device for the delayed release of a macromolecular drug compound

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5618531A (en) * 1990-10-19 1997-04-08 New York University Method for increasing the viability of cells which are administered to the brain or spinal cord
US5212082A (en) * 1991-03-13 1993-05-18 New York University Genetically modified tyrosine hydroxylase and uses thereof
EP0673259A4 (en) * 1992-01-23 1995-12-06 Univ New York METHOD FOR TRANSPLANTING CELLS INTO THE BRAIN AND THERAPEUTIC USE THEREOF.
JP3490447B2 (ja) * 1993-04-30 2004-01-26 フォトジェネシス インコーポレイテッド 網膜色素上皮移植
AU715177B2 (en) * 1994-04-13 2000-01-20 Research Corporation Technologies, Inc. Methods of treating disease using sertoli cells and allografts or xenografts
US5759536A (en) * 1994-05-27 1998-06-02 University Technology Corporation Use of fas ligand to supress T-lymphocyte-mediated immune responses

Also Published As

Publication number Publication date
EP1044024A1 (en) 2000-10-18
JP2002500202A (ja) 2002-01-08
AU759273B2 (en) 2003-04-10
CA2317115A1 (en) 1999-07-15
AU2019199A (en) 1999-07-26
NZ505459A (en) 2003-07-25
WO1999034834A1 (en) 1999-07-15
US20060147437A1 (en) 2006-07-06

Similar Documents

Publication Publication Date Title
JP4741189B2 (ja) 増殖した細胞系およびその使用方法
US6117675A (en) Retinal stem cells
EP1261357B1 (en) Isolation and transplantation of retinal stem cells
US7115257B1 (en) ARPE-19 as a platform cell line for encapsulated cell-based delivery
Klassen et al. Stem cells and retinal repair
CA2113118C (en) Novel growth factor-responsive progenitor cells which can be proliferated in vitro
Canola et al. Retinal stem cells transplanted into models of late stages of retinitis pigmentosa preferentially adopt a glial or a retinal ganglion cell fate
US20030125293A1 (en) Adipose tissue-derived stromal cells for the repair of corneal and intra-orbital defects and uses thereof
AU759273B2 (en) Use of retinal pigment epithelial cells for creation of an immune privilege site
JP2010018627A (ja) 血管の形成ならびに血管新生および栄養因子の生産に使用するための骨髄間質細胞に由来する物質
CN101801396A (zh) 治疗神经变性的方法和组合物
WO2005001072A1 (de) Isolierte adulte pluripotente stammzellen und verfahren zu deren isolierung und kultivierung
JP2022502047A (ja) ヒト網膜前駆細胞の単離および培養の方法
US12226452B2 (en) Polyhedrin-based slow release growth factor system for neuroprotection of retinal ganglion cell neurons
MXPA00006546A (en) Use of pigmented retinal epithelial cells for creation of an immune privilege site
US20090175833A1 (en) Pericytes for use as stem cells
WO2010030199A1 (en) Stem cell culture
RU2809003C2 (ru) Способы выделения и культивирования человеческих ретинальных клеток-предшественников
EP4176870A1 (en) Extracellular vesicles or composition thereof for use as a medicament, such as for the treatment of ocular surface disorders
Mitrousis A Bioengineering Approach Towards Retina Regeneration
CA2399589A1 (en) Novel growth factor-responsive progenitor cells which can be proliferated in vitro
HK1109784A (en) Adipose tissue-derived stromal cells for the repair of corneal and intra-orbital defects and uses thereof

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20000701

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20030804

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20050428

Patent event code: PE09021S01D

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20051125

Patent event code: PE09021S01D

E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20060510

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20051125

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I

Patent event date: 20050428

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I